&w=3840&q=100)
India approves Eli Lilly's Mounjaro pen for diabetes, weight control
Earlier in March, the company had launched Mounjaro in injectable vial form in 2.5 mg and 5 mg strengths.
What is Mounjaro KwikPen and how does it work?
According to Eli Lilly, the Mounjaro KwikPen is a multi-dose, single-patient-use, prefilled pen designed for once-weekly injections. It offers a more convenient way for people with type 2 diabetes and obesity to take their medication.
Mounjaro is the first and only drug that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors—two hormones that help regulate blood sugar and appetite.
In simple terms, Mounjaro helps:
Improve insulin production
Lower blood sugar levels
Reduce body weight
Control appetite
All six dosage options of Mounjaro (2.5 mg to 15 mg) will soon be available in India.
How does Mounjaro support weight management?
The drug acts on hunger-regulating centres in the brain and slows stomach emptying, helping users feel full for longer. Clinical data show it improves fat metabolism and reduces body fat, contributing to weight loss.
Who is eligible to use the Mounjaro KwikPen?
The KwikPen is approved as an adjunct treatment with diet and exercise for:
Adults with type 2 diabetes
Adults with obesity (BMI ≥ 30)
Overweight adults (BMI ≥ 27) with at least one weight-related condition such as high blood pressure or cholesterol
When will Mounjaro KwikPen be available in India?
While CDSCO has granted marketing authorisation, Lilly has not disclosed a launch date or pricing. The company has said this information will be announced soon.
Mounjaro in vial form is priced at ₹3,500 (2.5 mg) and ₹4,375 (5 mg).
Expert voices caution on long-term efficacy
Speaking to Business Standard, Dr Ashish Gautam, Senior Director, Robotic and Laparoscopic Surgery at Max Super Speciality Hospital, said:
'The response towards anti-obesity medication in India has been positive, but the long-term benefits are yet to be established. While the medicines show good results during usage, weight tends to come back once medication is stopped.'
He added that while drugs like Mounjaro are effective during use, bariatric surgery remains a more reliable long-term option for obesity.
Sales surge and new competition from Wegovy
According to PharmaTrac, Mounjaro has sold over 81,570 units in India as of May, with a 60 per cent rise in sales between April and May.
On Tuesday, Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in India. It is expected to hit pharmacies by the end of the month, according to Novo Nordisk India MD Vikrant Shrotriya.
India's obesity and diabetes burden continues to grow
The National Family Health Survey (NFHS)-5 (2019–21) found that 24 per cent of women and 23 per cent of men aged 15–49 were overweight or obese, a sharp rise from 2015–16.
The International Diabetes Federation projects that the number of adults with diabetes in India will grow from 74.2 million in 2021 to over 124 million by 2045.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
3 hours ago
- News18
Small Drugmakers Supplying Medicines In Rural Areas Under Scrutiny; Centre Calls For Crackdown
Central Drugs Standard Control Organisation has conducted over 1,000 Risk-Based Inspections across the country and asked states/UTs to continue acting after finding non-compliance. Small pharmaceutical companies, especially those supplying medicines in rural areas, have come under regulatory scrutiny, with the Drug Controller General of India (DCGI) directing state officials to closely monitor their activities and ensure accountability. The DCGI has asked states, via state licensing authorities (SLAs) to take strict action against any such marketers found violating quality standards under the Drugs and Cosmetics Rules, 1945. The move comes amid growing concerns over the quality and compliance practices of certain small-scale players in the drug distribution chain. The apex drug regulatory agency has also called for stricter action against the repeated manufacture of spurious and Not of Standard Quality (NSQ) drugs and asked states to keep CDSCO informed of any regulatory actions taken. 'We are still awaiting response on Schedule M compliance and most small players are unable to cope up with quality scrutiny. The government is convinced that without proper oversight, these companies pose a risk to medicine safety in under-served regions," a senior government official privy to the development told News18. The official added that the apex regulatory authority, Central Drugs Standard Control Organisation (CDSCO) has conducted over 1,000 Risk-Based Inspections (RBIs) across the country. 'These inspections have been key in identifying non-compliance among drug manufacturers and strengthening the surveillance framework." The first is adoption of revised Schedule M. The DCGI has asked state officials to begin enforcing updated Good Manufacturing Practice norms for drug production units. Also, it has asked to fix new drug licensing gaps as state licensing officials have been asked to refrain from issuing product licences without proper permissions from DCGI. The officials have also been instructed 'Post risk based inspections action." The states and UTs have been urged to act on the findings and recommendations that emerge from inspections. CDSCO has informed officials to comply with '84AB" in which details of all drug makers and product details must be uploaded and verified on the central online portal to ensure traceability. Also, the state officials will work on building testing lab capacity which has been flagged as a 'critical need."
Mint
5 hours ago
- Mint
Lilly and Novo are the kings of weight-loss drugs. The companies coming for their crowns.
Eli Lilly and Danish pharma giant Novo Nordisk are dominating the market for weight-loss drugs. But a number of competitors are hot on their heels. While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector. Any way you slice it, the market for weight-loss drugs like the so-called GLP-1 medication made by Lilly and Novo is likely to be huge. Morningstar is one of the most optimistic on this potential, seeing a $200 billion market by 2031. Goldman Sachs cut its estimate in April to $95 billion by 2030, down from $130 billion. That is arguably still a very large number and has attracted more companies to the lucrative industry. Both well-established pharma companies as well as smaller, clinical-stage firms are investing heavily to be able to someday compete with Lilly and Novo. Here's a look at some of the contenders: As one of the largest pharmaceutical companies in the U.S., Amgen has pockets deep enough to invest in the booming obesity drug space, and its drug MariTide has shown potential. Its distinct advantage over current jabs is that it would only have to be injected once a month, as opposed to once a week like Lilly's Zepbound and Novo's Wegovy. In a mid-stage trial, patients lost on average about 20% of their body weight after a year on MariTide, roughly on par with rivals, but a surprisingly large number of participants dropped out due to side effects. A late-stage trial is ongoing. Small cap Viking Therapeutics is a clinical-stage biotech and doesn't yet generate revenue. It announced as late as June 25 that it started a late-stage trial of its injectable weight-loss treatment VK2735. VK2735 is a so-called dual GLP-1 and GIP receptor, meaning it targets two different gut hormones to help control blood sugar levels and appetite, thereby helping patients lose unwanted weight. It's also conducting a mid-stage trial for VK2735 in pill form. An early-stage trial showed adults on the highest dosage of the drug lost on average 8.2% of their body weight in four weeks. This Danish up-and-comer has partnered with Roche and privately held Boehringer Ingelheim to develop next-generation weight-loss drugs. Zealand's portfolio includes medicines targeting both GLPs and GIPs receptors (Dapiglutide/Survodutide/ZP6590) as well as a so-called amylin analog (Petrelintide), which works differently from GLP-1s to increase feelings of fullness. There are hopes that amylin could produce fewer side effects than GLP-1 drugs. Structure Therapeutics is a San Francisco-based clinical-stage biotech that is also developing an amylin receptor agonist, ACCG-2671. It expects to start an early-stage trial of the drug by the end of 2025. Preclinical trials have shown significant weight-loss, but also less severe side effects and muscle mass preservation, according to Structure executives. The company also has an oral GLP-1 candidate in the pipeline. The U.K.'s most valuable company by market capitalization AstraZeneca is another Big Pharma player wanting to get into weight-loss drugs with its candidate AZD5004. The treatment is a small molecule oral GLP-1. Type 2 diabetes patients lost 5.8% of their body weight loss after four weeks of taking the daily pill, with mild to modest gastrointestinal side effects. The drug was licensed by AstraZeneca in 2023 from China's Eccogene and is currently in a mid-stage trial. It has two other injectable weight-loss drugs in the pipeline as well. Swiss-listed Roche is developing three different weight-loss drugs, one in partnership with Zealand Pharma. Its portfolio includes both oral and injectable weight-loss medicines, and both single and dual receptor antagonists. Hopes are high, especially for its oral version, but there have been concerns about side effects. Its jab is in a mid-stage trial while its pill is in an early-stage trial. Write to Elsa Ohlen at
New Indian Express
6 hours ago
- New Indian Express
Foreign medical residents fill critical positions at US hospitals amid Trump's visa crackdown
Some hospitals in the US are without essential staff because international doctors who were set to start their medical training this week were delayed by the Trump administration's travel and visa restrictions. It's unclear exactly how many foreign medical residents were unable to start their assignments, but six medical residents interviewed by The Associated Press say they've undergone years of training and work only to be stopped at the finish line by what is usually a procedural step. 'I don't want to give up,' said a permanent Canadian resident who matched to the University of Pittsburgh Medical Center Harrisburg but had her visa denied because she is a citizen of Afghanistan. She requested to remain anonymous for fear of reprisal. 'But the situation also seems so helpless.' Initially, the medical community was worried that hundreds of positions — many in hospitals in low-income or rural areas of the US — could be affected. The pause on interviews for J-1 visas for approved work or study-related programs was lifted in mid-June. The national nonprofit that facilitates the residency match process said the visa situation is resolving, but it will take weeks to know with confidence how many medical residents have had the start of their careers derailed because they got their visa too late or were blocked by US President Donald Trump's travel ban on 12 countries, according to people who coordinate the residents' training. Four foreign medical residents told the AP that US embassies have been slow to open up interview slots — and some have not opened any. 'You lose out on the time you could have used to treat patients,' said one resident from Pakistan, who matched to an internal medicine program in Massachusetts and requested to remain anonymous for fear of reprisal.
